Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

P239 Immunotherapy of Established Murine Squamous Cell Carcinoma Using Dendritic Cell–Tumor Fusion Hybrids

P239 Immunotherapy of Established Murine Squamous Cell Carcinoma Using Dendritic Cell–Tumor... Objective: To investigate the therapeutic efficacy of dendritic cell–tumor fusion hybrids against a murine squamous cell carcinoma (SCC) Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC in C3H (H-2K) mice. Subdermal tumors were established by inoculation in the midabdomen of mice. Tumor diameter were measured with a Veneer caliper and used as an indication of treatment efficacy. Dendritic cells were generated from bone marrow cells, cultured with cytokines for 8 days, harvested, and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse. Subjects: C3H mice. Interventions: Mice with 3-day established subdermal SCC VII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 × 106/side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibody or interleukin 12 was used. Treatment groups included no treatment, anti-OX40R monoclonal antibody, or interleukin 12 adjuvant alone, fusion cells alone, and fusion cells with adjuvant. Results: Mice treated with adjuvant or fusion cells alone did not show a statistical difference in tumor growth compared with controls. In contrast, mice treated with fusion cells and adjuvant showed a significant decrease in tumor size compared with untreated mice (P = .002). Conclusions: Dendritic cell–tumor fusion hybrid immunotherapy can significantly impact SCC VII growth, which supports the concept of using dendritic cell–tumor fusion cells as an immunotherapy approach against human SCC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Otolaryngology - Head & Neck Surgery American Medical Association

P239 Immunotherapy of Established Murine Squamous Cell Carcinoma Using Dendritic Cell–Tumor Fusion Hybrids

P239 Immunotherapy of Established Murine Squamous Cell Carcinoma Using Dendritic Cell–Tumor Fusion Hybrids

Abstract

Objective: To investigate the therapeutic efficacy of dendritic cell–tumor fusion hybrids against a murine squamous cell carcinoma (SCC) Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC in C3H (H-2K) mice. Subdermal tumors were established by inoculation in the midabdomen of mice. Tumor diameter were measured with a Veneer caliper and used as an indication of treatment efficacy. Dendritic cells were generated from bone marrow cells, cultured with cytokines for 8...
Loading next page...
 
/lp/american-medical-association/p239-immunotherapy-of-established-murine-squamous-cell-carcinoma-using-WBkqod1NOO
Publisher
American Medical Association
Copyright
Copyright © 2006 American Medical Association. All Rights Reserved.
ISSN
0886-4470
eISSN
1538-361X
DOI
10.1001/archotol.132.8.912-b
Publisher site
See Article on Publisher Site

Abstract

Objective: To investigate the therapeutic efficacy of dendritic cell–tumor fusion hybrids against a murine squamous cell carcinoma (SCC) Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC in C3H (H-2K) mice. Subdermal tumors were established by inoculation in the midabdomen of mice. Tumor diameter were measured with a Veneer caliper and used as an indication of treatment efficacy. Dendritic cells were generated from bone marrow cells, cultured with cytokines for 8 days, harvested, and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse. Subjects: C3H mice. Interventions: Mice with 3-day established subdermal SCC VII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 × 106/side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibody or interleukin 12 was used. Treatment groups included no treatment, anti-OX40R monoclonal antibody, or interleukin 12 adjuvant alone, fusion cells alone, and fusion cells with adjuvant. Results: Mice treated with adjuvant or fusion cells alone did not show a statistical difference in tumor growth compared with controls. In contrast, mice treated with fusion cells and adjuvant showed a significant decrease in tumor size compared with untreated mice (P = .002). Conclusions: Dendritic cell–tumor fusion hybrid immunotherapy can significantly impact SCC VII growth, which supports the concept of using dendritic cell–tumor fusion cells as an immunotherapy approach against human SCC.

Journal

Archives of Otolaryngology - Head & Neck SurgeryAmerican Medical Association

Published: Aug 1, 2006

Keywords: squamous cell carcinoma,immunotherapy,mice,dendritic cell neoplasms

There are no references for this article.